AbbVie Inc (ABBV) Shares Bought by Foster & Motley Inc.

Foster & Motley Inc. raised its holdings in shares of AbbVie Inc (NYSE:ABBV) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,307 shares of the company’s stock after buying an additional 337 shares during the quarter. Foster & Motley Inc.’s holdings in AbbVie were worth $4,177,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Horrell Capital Management Inc. acquired a new position in shares of AbbVie in the fourth quarter valued at $41,000. Massey Quick Simon & CO. LLC acquired a new position in shares of AbbVie in the fourth quarter valued at $64,000. Brand Asset Management Group Inc. raised its stake in shares of AbbVie by 60.7% in the fourth quarter. Brand Asset Management Group Inc. now owns 1,059 shares of the company’s stock valued at $98,000 after purchasing an additional 400 shares in the last quarter. Signature Estate & Investment Advisors LLC acquired a new position in shares of AbbVie in the third quarter valued at $112,000. Finally, LeJeune Puetz Investment Counsel LLC acquired a new position in shares of AbbVie in the fourth quarter valued at $145,000. Institutional investors own 68.40% of the company’s stock.

AbbVie stock opened at $81.34 on Friday. AbbVie Inc has a 52-week low of $75.77 and a 52-week high of $116.73. The firm has a market cap of $119.98 billion, a price-to-earnings ratio of 10.28, a P/E/G ratio of 1.19 and a beta of 1.17.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($0.02). AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. The company had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the prior year, the company earned $1.48 earnings per share. The business’s revenue was up 7.3% compared to the same quarter last year. Equities analysts anticipate that AbbVie Inc will post 8.68 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a dividend of $1.07 per share. The ex-dividend date is Friday, April 12th. This represents a $4.28 annualized dividend and a yield of 5.26%. AbbVie’s dividend payout ratio is currently 54.11%.

AbbVie announced that its Board of Directors has approved a stock repurchase program on Thursday, December 13th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

A number of research analysts recently commented on the company. Morgan Stanley set a $88.00 target price on AbbVie and gave the company a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Barclays restated a “hold” rating and issued a $86.00 target price on shares of AbbVie in a research note on Thursday, February 14th. Credit Suisse Group set a $79.00 target price on AbbVie and gave the company a “hold” rating in a research note on Friday, January 25th. Finally, ValuEngine lowered AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. AbbVie presently has a consensus rating of “Hold” and an average target price of $94.48.

In other news, EVP Azita Saleki-Gerhardt sold 15,797 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $79.03, for a total transaction of $1,248,436.91. Following the sale, the executive vice president now owns 93,312 shares in the company, valued at $7,374,447.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of the stock in a transaction on Friday, December 28th. The stock was sold at an average price of $90.00, for a total value of $2,250,000.00. Following the sale, the insider now owns 134,322 shares in the company, valued at approximately $12,088,980. The disclosure for this sale can be found here. Insiders have sold 90,797 shares of company stock valued at $7,748,437 over the last quarter. Corporate insiders own 0.07% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AbbVie Inc (ABBV) Shares Bought by Foster & Motley Inc.” was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.modernreaders.com/news/2019/03/17/abbvie-inc-abbv-shares-bought-by-foster-motley-inc.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C.

Featured Article: 52-Week High/Low Prices For Stock Selection

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply